Entering text into the input field will update the search result below

Can-Fite jumps 87% after namodenoson clears all lesions in Phase II liver cancer study

Human Liver Anatomy

magicmine/iStock via Getty Images

  • Can-Fite BioPharma (NYSE:CANF) soars 87.4% premarket after announcing that the last patient treated under an Open Label Extension program of its concluded Phase II study of Namodenoson in the treatment of hepatocellular carcinoma (HCC), experienced a

Recommended For You

About CANF Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
CANF--
Can-Fite BioPharma Ltd.